Company · Ownership research

Kiniksa Pharmaceuticals International, plc KNSA

CIK 0001730430

Form 4 transactions dated Nov 1, 2023 to Nov 10, 2026, as reported to the SEC.

Insider trading Initial holdings Institutional holders

This page lists 30 of 32 rows; the complete set is available through the API.

Insider filings on file run through Nov 6, 2026.

Some filings are submitted jointly by several insiders. The SEC form does not apportion the reported figures between them, so results include every joint filer.

Insider purchases & sales

Purchased: $0.00
Sold: $192.12M

Nov 1, 2023 – Nov 6, 2026
Available records · partial months are marked ·

202610 of 30 preview events · 32 available in 2026

Date	Insider	Activity	Trade value (USD)	% of prior holding
Nov 4, 2026	Patel Sanj K CHAIRMAN & CEO · Director	Sale10b5-1 footnote	$14.33M 151,300 shares sold	16.34% sold Trust holding	▾
Nov 3, 2026	Patel Sanj K CHAIRMAN & CEO · Director	Sale10b5-1 footnote	$20.54M 220,170 shares sold	22.01% sold Trust holding	▾
Nov 2, 2026	Moat Ross CHIEF OPERATING OFFICER	Sale10b5-1 footnote	$2.58M 27,977 shares sold	73.10% sold Direct holding	▾
Nov 2, 2026	Ragosa Mark CHIEF FINANCIAL OFFICER	Sale10b5-1 footnote	$3.39M 36,783 shares sold	63.82% sold Direct holding	▾
Nov 2, 2026	Paolini John F. CHIEF MEDICAL OFFICER	Sale10b5-1 footnote	$1.72M 18,413 shares sold	20.84% sold Direct holding	▾
Nov 2, 2026	Patel Sanj K CHAIRMAN & CEO · Director	Sale10b5-1 footnote	$8.22M 89,433 shares sold	9.32% sold Trust holding	▾
Oct 30, 2026	Moat Ross CHIEF OPERATING OFFICER	Sale10b5-1 footnote	$7.04M 75,608 shares sold	88.02% sold Direct holding	▾
Oct 30, 2026	Paolini John F. CHIEF MEDICAL OFFICER	Sale10b5-1 footnote	$7.22M 77,587 shares sold	52.60% sold Direct holding	▾
Oct 30, 2026	Patel Sanj K CHAIRMAN & CEO · Director	Sale10b5-1 footnote	$8.65M 92,891 shares sold	Unavailable Trust holding	▾
Oct 30, 2026	Megna Michael R CHIEF ACCOUNTING OFFICER	Sale10b5-1 footnote	$3.42M 36,260 shares sold	74.06% sold Direct holding	▾

Showing 30 / 32 record groups in 2026. The complete set is available through the API.

Kiniksa Pharmaceuticals International, plc · KNSA

Follow the people behind the trades.

Log in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and reach other datasets through the Akkru API.

Download CSV
Earlier filings
Advanced screening & filtering
API & AI access

Already have an account?

＋ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account. For the year shown, this page lists 30 of 32 purchase / sale groups and 30 of 234 other groups; the totals and the monthly series cover the whole window.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP / CLI.

MCP  https://api.akkrudata.ai/mcp

akkru_insider_transactions
{"action":"list","ticker":"KNSA","transaction_code":["P","S"],"transaction_form_type":"4","page_size":20}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint: https://api.akkrudata.ai/mcp
API / MCP / CLI documentation: /documents
llms.txt: /llms.txt

Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

Non-cancelled, non-derivative purchase (P) and sale (S) rows dated inside the public window, as reported. Share totals are on today's split-adjusted basis. Includes open-market and private transactions. Data after the latest filing is not asserted complete and is not zero-filled. A grouped event shares filing, transaction date, security, code, direction, ownership bucket and source. Derivative groups also match underlying security, exercise price, exercise/expiration dates and footnote references. Reported rows are retained; P/S price lots can be grouped. Post-transaction balances are never summed.